COMPARISON OF EFFICACY OF PDE5 INHIBITORS (SILDENAFIL) VERSUS ALPHA-BLOCKERS (TAMSULOSIN) IN TREATMENT OF LOWER URINARY TRACT SYMPTOMS (LUTS) SECONDARY TO BENIGN PROSTATIC HYPERPLASIA

IU HAQ; . SHAHJEHAN; G GHOUS; HR ASGHAR; A RIZWAN; U HANIF

doi:10.54112/bcsrj.v2024i1.749

Authors

IU HAQ Department of Urology, Unit 1 Mayo Hospital, Lahore, Pakistan
. SHAHJEHAN Department of Urology, King Edward Medical University, Lahore, Pakistan
G GHOUS Department of Urology, Mayo Hospital, Lahore, Pakistan
HR ASGHAR Department of Urology, Avicenna Medical College, Lahore, Pakistan
A RIZWAN Department of Urology, Mayo Hospital, Lahore, Pakistan
U HANIF Department of Urology, Mayo Hospital, Lahore, Pakistan

DOI:

https://doi.org/10.54112/bcsrj.v2024i1.749

Keywords:

Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms, Five Inhibitors Of Phosphodiesterase, Sildenafil, Tamsulosin.

Abstract

Benign prostatic hyperplasia (BPH) is a prevalent condition leading to lower urinary tract symptoms (LUTS) in men, affecting their quality of life. Various medications, including phosphodiesterase five inhibitors (PDE5-Is) and alpha-blockers (ABs), are used for treatment, but direct comparison studies between these drugs are limited. This study aimed to compare the efficacy of sildenafil (PDE5 inhibitor) versus tamsulosin (alpha-blocker) in patients with LUTS secondary to BPH. A randomized controlled trial was conducted at the Department of Urology, KEMU/Affiliated Hospital, Lahore. A sample size of 100 patients (50 in each group) was calculated using the WHO calculator based on expected efficacy rates. Patients aged 40-70 years with BPH and LUTS were included. Exclusion criteria included high PSA levels, history of prostatic surgery, acute urinary retention, or active urinary tract infection. Patients were randomly assigned to receive sildenafil 25mg OD or tamsulosin 0.4mg HS for three months. Efficacy was assessed by changes in the International Prostate Symptom Score (IPSS) after treatment. The demographic characteristics of the study population showed a mean age of 60 years with a similar distribution of comorbidities between the groups. After three months of treatment, 80.9% of patients in the sildenafil group showed a significant improvement in IPSS compared to 55.5% in the tamsulosin group. The chi-square test indicated a significant difference in efficacy between the two groups (p < 0.05). Sildenafil demonstrated superior efficacy compared to tamsulosin in reducing LUTS secondary to BPH. These findings suggest that sildenafil may be considered as a first-line treatment option for patients with BPH and LUTS.

Downloads

Download data is not yet available.

References

Calogero, A. E., Burgio, G., Condorelli, R. A., Cannarella, R., and La Vignera, S. (2018). Treatment of lower urinary tract symptoms/benign prostatic hyperplasia and erectile dysfunction. The Aging Male 21, 272-280.

Chapple, C. R., Montorsi, F., Tammela, T. L., Wirth, M., Koldewijn, E., Fernández, E. F., and Group, E. S. S. (2011). Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo-and active-controlled clinical trial performed in Europe. European urology 59, 342-352.

de Boer, M. K., Schoevers, R. A., Ruhé, H. G., and Knegtering, H. (2014). From effects of psychotropic medication to mechanisms of sexual functioning: a clinically oriented review. Antipsychotic treatment and sexual functioning 33, 22-46.

De Nunzio, C., Lombardo, R., Cicione, A. M., and Tubaro, A. (2020). Benign prostatic hyperplasia (BPH). Urologic principles and practice, 341-355.

Fawzi, A., Kamel, M., Salem, E., Desoky, E., Omran, M., Elgalaly, H., Sakr, A., Maarouf, A., and Khalil, S. (2017). Sildenafil citrate in combination with tamsulosin versus tamsulosin monotherapy for management of male lower urinary tract symptoms due to benign prostatic hyperplasia: A randomised, double-blind, placebo-controlled trial. Arab Journal of Urology 15, 53-59.

Iheanacho, C. O., Okwesilieze, C. N., and Eyong, A. K. (2022). Role of calcium channel blockers in lower urinary tract symptoms in benign prostatic hyperplasia: a literature review. African Journal of Urology 28, 51.

Kreutzwiser, D., and Tseng, A. (2016). Drug interactions between antiretrovirals and drugs used to treat benign prostatic hyperplasia/lower urinary tract symptoms. Expert Opinion on Drug Metabolism & Toxicology 12, 1211-1224.

Olesovsky, C., and Kapoor, A. (2016). Evidence for the efficacy and safety of tadalafil and finasteride in combination for the treatment of lower urinary tract symptoms and erectile dysfunction in men with benign prostatic hyperplasia. Therapeutic Advances in Urology 8, 257-271.

Park, S., Ryu, J.-m., and Lee, M. (2020). Quality of life in older adults with benign prostatic hyperplasia. In "Healthcare", Vol. 8, pp. 158. MDPI.

Pattanaik, S., Sandhu, H. S., Mavuduru, R. S., Singh, S. K., and Mandal, A. K. (2019). Efficacy of tamsulosin and tadalafil in relieving benign prostatic hyperplasia related symptoms: a randomized double blind placebo controlled cross-over study. Indian Journal of Urology 35, 25-33.

Romics, I. (2007). The role of alpha-adrenoreceptors in the treatment of urological diseases. Neurochemistry international 51, 328-331.

Russo, G. I., Urzì, D., and Cimino, S. (2018). Epidemiology of LUTS and BPH. In "Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia", pp. 1-14. Elsevier.

Thomas, D., Chughtai, B., Kini, M., and Te, A. (2017). Emerging drugs for the treatment of benign prostatic hyperplasia. Expert Opinion on Emerging Drugs 22, 201-212.

Ückert, S., Kedia, G. T., Tsikas, D., Simon, A., Bannowsky, A., and Kuczyk, M. A. (2020). Emerging drugs to target lower urinary tract symptomatology (LUTS)/benign prostatic hyperplasia (BPH): focus on the prostate. World journal of urology 38, 1423-1435.

Yu, Z.-J., Yan, H.-L., Xu, F.-H., and Chao, H.-C. (2020). Efficacy and side effects of drugs commonly used for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. Frontiers in Pharmacology 11, 528249.